From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors.
暂无分享,去创建一个
Jun Liang | P. Trojer | Y. Ran | R. Cummings | Amy Gustafson | Yichin Liu | P. Dragovich | Birong Zhang | B. Liederer | M. Vinogradova | J. Kiefer | Tommy Lai | Jiangpeng Liao | Victor S. Gehling | J. Harmange | D. Ortwine | M. Classon | Weifeng Mao | Snahel Patel | S. Labadie | Lesley J. Murray | Xiaoping Zheng | Le An | Gauri Deshmukh | Till Mauer | Erica Van der Porten
[1] Akane Kawamura,et al. Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells , 2017, Cell chemical biology.
[2] Jun Liang,et al. Design and evaluation of 1,7-naphthyridones as novel KDM5 inhibitors. , 2016, Bioorganic & medicinal chemistry letters.
[3] P. Trojer,et al. Identification of potent, selective KDM5 inhibitors. , 2016, Bioorganic & medicinal chemistry letters.
[4] Jun Liang,et al. Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies. , 2016, Bioorganic & medicinal chemistry letters.
[5] M. Chandrasekar,et al. Inhibitors of histone deacetylase as antitumor agents: A critical review. , 2016, Bioorganic chemistry.
[6] Margaret A. Johns,et al. Structural Basis for KDM5A Histone Lysine Demethylase Inhibition by Diverse Compounds. , 2016, Cell chemical biology.
[7] P. Trojer,et al. An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells. , 2016, Nature chemical biology.
[8] R. Prinjha,et al. Structural analysis of human KDM5B guides histone demethylase inhibitor development. , 2016, Nature chemical biology.
[9] Akane Kawamura,et al. Recent Progress in Histone Demethylase Inhibitors. , 2016, Journal of medicinal chemistry.
[10] Douglas W. Thomson,et al. Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 1. 3-Amino-4-pyridine Carboxylate Derivatives. , 2016, Journal of medicinal chemistry.
[11] David M. Wilson,et al. Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 2. Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives. , 2016, Journal of medicinal chemistry.
[12] G. F. Ruda,et al. 8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors , 2016, Journal of medicinal chemistry.
[13] Kristian Helin,et al. Histone lysine demethylases as targets for anticancer therapy , 2013, Nature Reviews Drug Discovery.
[14] P. Gimotty,et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. , 2013, Cancer cell.
[15] Yukihiro Itoh,et al. Small-molecular modulators of cancer-associated epigenetic mechanisms. , 2013, Molecular bioSystems.
[16] J. Whetstine,et al. Histone lysine methylation dynamics: establishment, regulation, and biological impact. , 2012, Molecular cell.
[17] Kristian Helin,et al. Molecular mechanisms and potential functions of histone demethylases , 2012, Nature Reviews Molecular Cell Biology.
[18] E. Greer,et al. Histone methylation: a dynamic mark in health, disease and inheritance , 2012, Nature Reviews Genetics.
[19] S. Yokoyama,et al. Structural basis for histone H3 Lys 27 demethylation by UTX/KDM6A. , 2011, Genes & development.
[20] Takayoshi Suzuki,et al. Lysine demethylases inhibitors. , 2011, Journal of medicinal chemistry.
[21] K. Helin,et al. Inhibitors of histone demethylases. , 2011, Bioorganic & medicinal chemistry.
[22] Ben S. Wittner,et al. A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.
[23] D. Reinberg,et al. Chromatin structure and the inheritance of epigenetic information , 2010, Nature Reviews Genetics.
[24] P. Leeson,et al. The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.
[25] Juri Rappsilber,et al. The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3 , 2006, Nature.
[26] Nicola Mongelli,et al. Rapid NMR‐based functional screening and IC50 measurements performed at unprecedentedly low enzyme concentration , 2005 .
[27] A. Hopkins,et al. Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.
[28] P. Marks,et al. Histone deacetylases and cancer: causes and therapies , 2001, Nature Reviews Cancer.